| Name | ATN-161 trifluoroacetate salt |
| Description | ATN-161 trifluoroacetate salt (ATN-161 TFA salt) is a novel integrin α5β1 antagonist that inhibits angiogenesis and growth of liver metastases and improves survival in a murine model. |
| In vitro | The co-administration of ATN-161 and 5-FU markedly reduces tumor cell growth more effectively than either treatment alone or the control. Additionally, this combined approach markedly elevates the levels of apoptotic (TUNEL-positive) tumor cells, a result not observed with single-agent treatments. Furthermore, ATN-161 demonstrates a 21% reduction in endothelial cell (EC) numbers after 48 hours compared to controls, highlighting its effectiveness. Importantly, ATN-161 also impedes VEGF-induced endothelial cell migration and capillary formation, although it does not affect their proliferation. It significantly decreases endothelial cell migration towards VEGF in a dose-dependent manner, beginning at 100 nM (P<0.001 vs. VEGF group), showcasing its potential in inhibiting angiogenesis[1][2]. |
| In vivo | Initial tests on α5β1-negative human colon cancer xenografts (HT29) show ATN-161 significantly decreases tumor weight and vessel density [1]. Administering ATN-161 post-laser photocoagulation effectively suppresses choroidal neovascularization (CNV) leakage and new blood vessel formation, achieving results comparable to those with AF564 [2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : Slightly soluble
|
| Keywords | ATN 161 trifluoroacetate salt | ATN 161 Trifluoroacetate | ATN161 trifluoroacetate salt | ATN-161 TFA | ATN161 | inhibit | ATN-161 | ATN 161 | Integrin | Inhibitor | ATN-161 Trifluoroacetate | ATN161 Trifluoroacetate |
| Inhibitors Related | K34c hydrochloride | E7820 | Arg-Gly-Asp TFA (99896-85-2(free base)) | Tirofiban hydrochloride monohydrate | Lifitegrast | Elarofiban TFA | Cyclo(-RGDfK) | Tirofiban | Bestatin hydrochloride | RO0270608 | ICAM-1-IN-1 | Gantofiban |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
